Approximately one in five women aged 18-35 in the United States uses Flo App. Similar penetration exists in the UK. Now the world’s most popular women’s health platform is pursuing something unprecedented: transitioning from wellness app to FDA-ready medical device.
The scale is staggering. Over 420 million people globally have downloaded the platform. The femtech unicorn achieved billion-dollar valuation in 2024 following a $200 million Series C round—becoming Europe’s first purely digital women’s health company to reach that milestone.
What makes this transition remarkable is the speed and methodology. The company built FDA-ready infrastructure in just 87 days without slowing the pace of innovation. Engineers still release daily and run over 1,000 A/B tests annually. The regulatory readiness happened alongside business-as-usual operations.
The implications for users are significant. Features like the recently launched perimenopause tracking and comprehensive symptom monitoring tools represent wellness features today. Tomorrow, clinical-grade symptom evaluations, risk assessments, and AI-powered diagnostic insights could reach one in five American women through an interface they already trust.
For the healthcare system, this represents both opportunity and disruption. Clinical-grade capabilities delivered through consumer channels could transform how women access health insights—and one in five is just the starting point.